EXHIBIT 99.1


          SIMULATIONS PLUS APPROVED TO LIST ON AMERICAN STOCK EXCHANGE

                     COMPANY TO TRADE UNDER NEW SYMBOL "SPL"

         LANCASTER, CA, MARCH 9, 2004. Simulations Plus, Inc. (OTCBB: SIMU), the
leading provider of ADME absorption simulation and neural net
structure-to-property prediction software for pharmaceutical discovery and
development, today announced that it has been approved for listing on the
American Stock Exchange and expects to commence trading under the ticker symbol
"SPL" beginning Wednesday, March 17, 2004.

         Walt Woltosz, chairman and chief executive officer of Simulations Plus,
said, "The Amex listing is another big step in our ongoing efforts to maximize
shareholder value. We set a goal last fiscal year to move from the OTCBB to a
listed exchange, and we have now achieved that goal. We believe that the
American Stock Exchange is the best place for our stock at this stage of the
company's growth. We expect it to raise our profile and give us access to a much
broader investor base, increasing interest in Simulations Plus among both retail
and institutional investors. The listing illustrates the progress we have made
in establishing Simulations Plus as a successful business as well as a leading
provider of simulation and modeling software to the global pharmaceutical
industry."

         The Company's securities were approved for listing on the American
Stock Exchange based upon a review by an Exchange Listing Qualifications Panel
which authorized approval of the listing pursuant to Section 1203(c) of the
American Stock Exchange Company Guide, notwithstanding the fact that the Company
does not fully satisfy the Exchange's regular initial listing standards with
respect to the $4 million shareholders' equity requirement. The Panel's decision
was based upon its determination that the Company satisfies the Exchange's
minimum Alternative Listing Standards and its affirmative finding that
mitigating factors warrant listing pursuant to the Alternative Listing
Standards. Specifically, the Panel noted the Company's impressive software
products for pharmaceutical research and for education and its current and
prospective relationships with pharmaceutical industry leaders. The Panel also
noted the Company's recent financial results, which include positive trends in
revenues and earnings.

ABOUT SIMULATIONS PLUS, INC.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery
and development simulation software, which is licensed to and used in the
conduct of drug research by major pharmaceutical and biotechnology companies
worldwide. The Company has two other businesses, Words+, Inc. and FutureLab(TM),
which are based on its proprietary software technologies. Simulations Plus,
Inc., is headquartered in Southern California and trades on the OTCBB under the
symbol "SIMU." For more information, visit our Web site at
www.simulations-plus.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
- With the exception of historical information, the matters discussed in this
press release are forward-looking statements that involve a number of risks and
uncertainties. The actual future results of the Company could differ
significantly from those statements. Factors that could cause or contribute to
such differences include, but are not limited to: the actual demand for the
Company's stock after listing on the American Stock Exchange, the ability of the
Company to maintain its competitive advantage, the general economics of the
pharmaceutical industry, the ability of the Company to attract and retain
sufficient scientific and technical staff to sustain its R&D and customer
support functions, and a sustainable market. Further information on the
Company's risk factors is contained in the Company's quarterly and annual
reports as filed with the Securities and Exchange Commission.

                                       ###